PENZBERG, Germany--(BUSINESS WIRE)-- With “Size: Reduced. Fun: Amplified.”, Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) launched its new real-time PCR system on June 27th, 2011. The small, silent, sleek LightCycler® Nano Instrument supports state-of-the-art technology for fast PCR protocols featuring leading edge thermal resolution and reproducibility. This powerful newcomer to the LightCycler® family offers plenty of options in an incredibly small platform.
As reported earlier, the LightCycler® Nano Real-Time PCR System is the product of an exclusive OEM agreement with IT-IS Life Sciences Ltd (UK and Ireland), using proprietary Roche dyes and reagents for precise and reproducible DNA amplification and melting curve analysis. Complete spectral information is provided for a broad range of dyes, supporting all state-of-the art assay formats and real-time PCR applications.
With the LightCycler® Nano System, Roche Applied Science has created something special. Intuitive in design and capable of being used with or without a personal computer, researchers will have more fun acquiring cutting-edge results! The LightCycler® Nano System can be used in networks, and does not require a dedicated computer. Either a preferred Mac, PC, or Linux Operating System, or simply a USB stick can be used to start a run.
Gerd Haberhausen, Life Cycle Leader qPCR and Nucleic Acid Preparation at Roche Applied Science, reported that “Like all LightCycler® Real-Time PCR Instruments, the LightCycler® Nano Real-Time PCR Instrument produces high quality qPCR, genotyping and high resolution melting data using easy-fit reagents, reaction vessels and instrumentation.” He adds: “The LightCycler® Nano Real-Time PCR System was built to enjoy in every lab, on every bench. Serious PCR and fun!”
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For life science research only. Not for use in diagnostic procedures.
LIGHTCYCLER is a trademark of Roche.
Other brands or product names are trademarks of the respective holder.
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
KEYWORDS: Europe Germany Switzerland
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Medical Devices Pharmaceutical